{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:41:19Z","timestamp":1769110879132,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Clinical Research Network","award":["PT17\/0017\/0003"],"award-info":[{"award-number":["PT17\/0017\/0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Circulating antigen carbohydrate 125 (CA125) has emerged as a proxy of fluid overload in heart failure. This study aimed to evaluate the effect of dapagliflozin on short-term CA125 levels in patients with stable heart failure with reduced ejection fraction (HFrEF) and whether these changes mediated the effects on peak oxygen consumption (peakVO<jats:sub>2<\/jats:sub>). This study is a post-hoc sub-analysis of a randomized, double-blinded clinical trial in which 90 stable patients with HFrEF were randomly assigned to receive either dapagliflozin or placebo to evaluate change in peakVO<jats:sub>2<\/jats:sub> (NCT04197635). We used linear mixed regression analysis to compare changes in the natural logarithm of CA125 (logCA125) and percent changes from baseline (\u0394%CA125). We used the \u201crwrmed\u201d package to perform mediation analyses. CA125 was available in 87 patients (96.7%). LogCA125 significantly decreased in patients on treatment with dapagliflozin [1-month: \u0394 \u2212\u00a00.18, (CI 95%\u2009=\u2009\u2212\u00a00.33 to \u2212\u00a00.22) and 3-month: \u0394 \u2212\u00a00.23, (CI 95%\u2009=\u2009\u2212\u00a00.38 to \u2212\u00a00.07); omnibus p-value\u2009=\u20090.012]. \u0394%CA125 decreased by 18.4% and 31.4% at 1 and 3-month, respectively (omnibus p-value\u2009=\u20090.026). Changes in logCA125 mediated the effect on peakVO<jats:sub>2<\/jats:sub> by 20.4% at 1\u00a0month (p\u2009&lt;\u20090.001). We did not find significant changes for natural logarithm of NTproBNP (logNT-proBNP) [1-month: \u0394 \u2212\u00a00.03, (CI 95%\u2009=\u2009\u2212\u00a00.23 to 0.17; p\u2009=\u20090.794), and 3-month: \u0394 0.73, (CI 95%\u2009=\u2009\u2212\u00a00.13 to 0.28; p-value 0.489), omnibus p-value\u2009=\u20090.567]. In conclusion, in patients with stable HFrEF, dapagliflozin resulted in a significant reduction in CA125. Dapagliflozin was not associated with short-term changes in natriuretic peptides. These changes mediated the effects on peakVO<jats:sub>2.<\/jats:sub><\/jats:p>","DOI":"10.1038\/s41598-023-37491-5","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T06:02:59Z","timestamp":1688104979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction"],"prefix":"10.1038","volume":"13","author":[{"given":"Martina","family":"Amiguet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Palau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloy","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Seller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Manuel Garcia","family":"Pinilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"de la Espriella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Mi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Sanchis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Bay\u00e9s-Gen\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"DAPA VO2 investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloy","family":"Dom\u00edngueza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Mi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Santas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mollar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Civera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Conesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim","family":"Zakarne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainoha","family":"Larumbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Manuel Garcia","family":"Pinilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jose G\u00f3mez","family":"Doblas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa Robles","family":"Mezcua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Mi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicent","family":"Bod\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domingo","family":"Pascual-Figal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara Jim\u00e9nez","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro I. P\u00e9rez","family":"Cabeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arancha D\u00edaz","family":"Exp\u00f3sito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 David Mart\u00ednez","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Luna","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J. Zafra","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel Montiel","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herminio Morillas","family":"Climent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"37491_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"37491_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cardfail.2021.07.003","volume":"27","author":"P Bjornstad","year":"2021","unstructured":"Bjornstad, P. et al. The potential roles of osmotic and nonosmotic sodium handling in mediating the effects of sodium-glucose cotransporter 2 inhibitors on heart failure. J. Cardiac. Fail. 27, 1447\u20131455 (2021).","journal-title":"J. Cardiac. Fail."},{"key":"37491_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ejhf.2066","volume":"23","author":"EM Boorsma","year":"2021","unstructured":"Boorsma, E. M. et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur. J. Heart Fail. 23, 68\u201378 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"37491_CR4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/ejhf.2295","volume":"23","author":"J N\u00fa\u00f1ez","year":"2021","unstructured":"N\u00fa\u00f1ez, J. et al. Antigen carbohydrate 125 as a biomarker in heart failure: A narrative review. Eur. J. Heart Fail. 23, 1445\u20131457 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"37491_CR5","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2021.22","volume":"7","author":"M Kumric","year":"2021","unstructured":"Kumric, M. et al. Carbohydrate antigen 125: A biomarker at the Crossroads of congestion and inflammation in heart failure. Card. Fail. Rev. 7, e19 (2021).","journal-title":"Card. Fail. Rev."},{"issue":"339","key":"37491_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijcard.2021.06.045","volume":"15","author":"R de la Espriella","year":"2021","unstructured":"de la Espriella, R. et al. Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure. Int. J. Cardiol. 15(339), 102\u2013105 (2021).","journal-title":"Int. J. Cardiol."},{"key":"37491_CR7","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/ejhf.2560","volume":"24","author":"P Palau","year":"2022","unstructured":"Palau, P. et al. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): A randomized clinical trial. Eur. J. Heart Fail. 24, 1816\u20131826 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"37491_CR8","first-page":"559","volume":"21","author":"A Linden","year":"2021","unstructured":"Linden, A., Huber, C. & Wodtke, G. T. A regression-with-residuals method for analyzing causal mediation: The rwrmed package. Stand. Genom. Sci. 21, 559\u2013574 (2021).","journal-title":"Stand. Genom. Sci."},{"key":"37491_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.recesp.2021.01.023","volume":"75","author":"J N\u00fa\u00f1ez","year":"2022","unstructured":"N\u00fa\u00f1ez, J. et al. Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. Rev. Espa\u00f1. Cardiol. 75, 316\u2013324 (2022).","journal-title":"Rev. Espa\u00f1. Cardiol."},{"key":"37491_CR10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ejhf.2664","volume":"24","author":"J N\u00fa\u00f1ez","year":"2022","unstructured":"N\u00fa\u00f1ez, J. et al. Congestion in heart failure: A circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. Eur. J. Heart Fail. 24, 1751\u20131766 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"37491_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jchf.2019.12.010","volume":"8","author":"NE Ibrahim","year":"2020","unstructured":"Ibrahim, N. E. et al. Natriuretic peptides as inclusion criteria in clinical trials: A JACC: Heart failure position paper. JACC Heart Fail. 8, 347\u2013358 (2020).","journal-title":"JACC Heart Fail."},{"key":"37491_CR12","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1002\/ehf2.13615","volume":"8","author":"D Fitchett","year":"2021","unstructured":"Fitchett, D. et al. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail. 8, 4517\u20134527 (2021).","journal-title":"ESC Heart Fail."},{"key":"37491_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008837","volume":"14","author":"JH Butt","year":"2021","unstructured":"Butt, J. H. et al. Efficacy and safety of dapagliflozin in Heart Failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: Insights from the DAPA-HF trial. Circ. Heart Fail. 14, e008837 (2021).","journal-title":"Circ. Heart Fail."},{"key":"37491_CR14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"37491_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens, W. et al. Acetazolamide in acute decompensated heart failure with volume overload. N. Engl. J. Med. 387, 1185\u20131195 (2022).","journal-title":"N. Engl. J. Med."},{"key":"37491_CR16","first-page":"67","volume":"95","author":"R de la Espriella","year":"2022","unstructured":"de la Espriella, R. et al. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. Eur. J. Heart Fail. 95, 67\u201373 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"37491_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41598-022-05328-2","volume":"12","author":"G Mi\u00f1ana","year":"2022","unstructured":"Mi\u00f1ana, G. et al. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction. Sci. Rep. 12, 1344 (2022).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37491-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37491-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37491-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T06:11:25Z","timestamp":1688105485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37491-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37491"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-37491-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. reports speaker fees from Astra Zeneca and Boehringer Ingelheim. JMGP reports personal fees from Astra Zeneca and Esteve. JMGP reports personal fees from Astra Zeneca and Esteve. AV reports speaker fees from Astra Zeneca. R.E. reports personal fees from Astra Zeneca, Novartis, Boehringer-Ingelheim, and NovoNordisk. AV reports speaker fees from Astra Zeneca. JS has received speaker fees from Abbott Vascular and Prosm\u00e9dica. JLG has received fees for participating in advisory boards and educational activities from Astra Zeneca, Boehringer-Ingelheim, NovoNordisk, Bayer, and Novartis. A.B.-G. has lectured and\/or participated in advisory boards for Abbott, Astra Zeneca, Boehringer-Ingelheim, Novartis, Roche Diagnostics, and Vifor. J.N. reports personal fees from Astra Zeneca, Novartis, Boehringer-Ingelheim, Eli Lilly, Rovi, NovoNordisk, and Vifor Pharma. Other authors do not have competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10591"}}